Several brokerages have updated their recommendations and price targets on shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) in the last few weeks:
- 8/28/2026 – Jazz Pharmaceuticals was given a new $299.00 price target by Royal Bank Of Canada.
- 8/26/2026 – Jazz Pharmaceuticals had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $277.00 price target on the stock.
- 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $283.00 to $322.00. They now have an “overweight” rating on the stock.
- 8/26/2026 – Jazz Pharmaceuticals was given a new $300.00 price target by Canaccord Genuity Group Inc..
- 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Deutsche Bank Aktiengesellschaft from $287.00 to $300.00. They now have a “buy” rating on the stock.
- 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Truist Financial Corporation from $264.00 to $281.00. They now have a “buy” rating on the stock.
- 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $292.00 to $310.00. They now have a “buy” rating on the stock.
- 8/11/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $280.00 to $283.00. They now have an “overweight” rating on the stock.
- 8/4/2026 – Jazz Pharmaceuticals was upgraded by Weiss Ratings from “hold (c-)” to “buy (b-)”.
- 8/4/2026 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $287.00 price target on the stock.
- 8/4/2026 – Jazz Pharmaceuticals had its price target raised by TD Cowen from $275.00 to $300.00. They now have a “buy” rating on the stock.
- 8/4/2026 – Jazz Pharmaceuticals was given a new $264.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
- 8/4/2026 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by UBS Group AG. They now have a $315.00 price target on the stock.
- 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $285.00 to $300.00. They now have an “overweight” rating on the stock.
- 8/4/2026 – Jazz Pharmaceuticals was given a new $275.00 price target by Stifel Nicolaus.
- 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Piper Sandler from $301.00 to $310.00. They now have an “overweight” rating on the stock.
- 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $260.00 to $270.00. They now have an “overweight” rating on the stock.
- 8/4/2026 – Jazz Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $265.00 to $276.00. They now have an “overweight” rating on the stock.
- 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $245.00 to $280.00. They now have an “overweight” rating on the stock.
- 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Robert W. Baird from $252.00 to $280.00. They now have an “outperform” rating on the stock.
- 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $282.00 to $292.00. They now have a “buy” rating on the stock.
- 7/20/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $255.00 to $282.00. They now have a “buy” rating on the stock.
- 7/16/2026 – Jazz Pharmaceuticals is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $290.00 price target on the stock.
- 7/16/2026 – Jazz Pharmaceuticals was upgraded by Canaccord Genuity Group Inc. to “strong-buy”.
- 7/14/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $265.00 to $285.00. They now have an “overweight” rating on the stock.
- 7/14/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $253.00 to $260.00. They now have an “overweight” rating on the stock.
- 7/9/2026 – Jazz Pharmaceuticals had its price target raised by Deutsche Bank Aktiengesellschaft from $250.00 to $270.00. They now have a “buy” rating on the stock.
- 7/7/2026 – Jazz Pharmaceuticals had its price target lowered by Truist Financial Corporation from $256.00 to $254.00. They now have a “buy” rating on the stock.
Insider Activity at Jazz Pharmaceuticals
In other Jazz Pharmaceuticals news, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the completion of the sale, the executive vice president owned 65,686 shares of the company’s stock, valued at approximately $16,401,794.20. The trade was a 53.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $252.98, for a total value of $1,517,880.00. Following the sale, the director owned 360,682 shares in the company, valued at approximately $91,245,332.36. The trade was a 1.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 91,278 shares of company stock valued at $22,712,816 over the last three months. 4.10% of the stock is owned by corporate insiders.
Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.
Read More
- Five stocks we like better than Jazz Pharmaceuticals
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.
